May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin®) for Macular Edema Secondary to Central Vein Occlusions
Author Affiliations & Notes
  • J. R. Gaitan
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • N. Z. Gregori
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • P. J. Rosenfeld
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • C. A. Puliafito
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • S. Dubovy
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • A. M. Berrocal
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • L. Al-Attar
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • H. W. Flynn
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • W. E. Smiddy
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • W. Feuer
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
  • Footnotes
    Commercial Relationships J.R. Gaitan, None; N.Z. Gregori, None; P.J. Rosenfeld, Genentech, Eyetech, and Alcon Laboratories, F; Genentech, Eyetech Pharmaceuticals, Novartis Ophthalmics, Allergan, Protein Design Labs, Tanox, Genaera, Jerini AG, Quark Inc, and Athenagen, C; Genentech, Eyetech, and Novartis Ophthalmics, Zeiss Meditec, R; C.A. Puliafito, Carl Zeiss Meditec, P; Genentech, Eyetech Pharmaceuticals, Pfizer, Carl Zeiss Meditec, R; S. Dubovy, None; A.M. Berrocal, None; L. Al-Attar, Pfizer, C; Pfizer, R; H.W. Flynn, Alcon Laboratories, Eyetech, Genentech, Eli Lilly, Novartis, Optimedica, Pfizer, C; W.E. Smiddy, None; W. Feuer, None.
  • Footnotes
    Support Supported by an unrestricted grant to the University of Miami from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 302. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. R. Gaitan, N. Z. Gregori, P. J. Rosenfeld, C. A. Puliafito, S. Dubovy, A. M. Berrocal, L. Al-Attar, H. W. Flynn, W. E. Smiddy, W. Feuer; Intravitreal Bevacizumab (Avastin®) for Macular Edema Secondary to Central Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):302.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate safety and efficacy of intravitreal bevacizumab (Avastin®, Genentech) for the treatment of macular edema (ME) secondary to central vein occlusions (CRVO).

Methods:: A retrospective review was performed of eyes treated with intravitreal bevacizumab for ME secondary to CRVO at the Bascom Palmer Eye Institute from June 2005 to July 2006. All patients underwent routine Snellen visual acuity (VA) assessment and OCT imaging with 1 mm central retinal thickness (CRT) measurements as part of their routine clinical care. The dose of bevacizumab was 1.25 mg (0.05 ml). Retreatment was performed at monthly intervals at the discretion of the treating physician.

Results:: Forty four eyes of 44 patients were identified. Forty patients returned at 1 month, 37 at 3 months, and 19 at 6 months. Mean VA was 17 letters at baseline, 28 at 1 month, 31 at 3 months, and 26 at 6 months. Patients gained a mean of 13 ETDRS letters at 1 month (p<0.001), 13 letters at 3 months (p<0.001), and 6 letters at 6 months (p=0.016). VA increased by at least 3 lines in 63% at 1 month, 54% at 3 months, and 37% at 6 months. The mean CRT was 636 µm at baseline, 313 µm at 1 month (p<0.001, n=28), 462 µm at 3 months (p=0.001, n=32), and 464 µm at 6 months (p=0.009, n=13). VA loss of 3 Snellen lines occurred in 3% at 1 month and 5% at 3 and 6 months. Thirty four (79%) eyes received >1 injection by 6 months of follow-up.

Conclusions:: Improvements in VA and OCT central retinal thickness measurements were observed through 6 months following intravitreal bevacizumab in patients with CRVO. These retrospective results support efforts to prospectively investigate intravitreal bevacizumab for the treatment of macular edema in retinal vein occlusions.

Keywords: vascular occlusion/vascular occlusive disease • drug toxicity/drug effects • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×